Table 7.
Comparison of TACE-Related Adverse Reactions Between the TACE Plus Sorafenib and TACE Alone Treatment Groups
| Adverse Event (n/%) | Group | χ2 | P | ||
|---|---|---|---|---|---|
| TACE Plus Sorafenib (n=42) | TACE Alone (n=43) | ||||
| New ascites | With | 3 (7.14%) | 4 (9.30%) | 0.131 | 0.513 |
| Without | 39 (92.86%) | 39 (90.70%) | |||
| Liver injury | With | 6 (14.29%) | 7 (16.28%) | 0.065 | 0.519 |
| Without | 36 (85.71%) | 36 (83.72%) | |||
| Hepatorenal syndrome | With | 1 (2.38%) | 1 (2.33%) | 0.000 | 0.747 |
| Without | 41 (97.62%) | 42 (97.67%) | |||
| Pleural effusion | With | 2 (4.76%) | 3 (6.98%) | 0.188 | 0.511 |
| Without | 40 (95.24%) | 40 (93.02%) | |||
| Spontaneous bacterial peritonitis | With | 1 (2.38%) | 0 (0.00%) | 1.036 | 0.494 |
| Without | 41 (97.62%) | 43 (100.00%) | |||
| Gastrointestinal bleeding | With | 2 (4.76%) | 1 (2.33%) | 0.370 | 0.491 |
| Without | 40 (95.24%) | 42 (97.67%) | |||
| Ischemic cholecystitis | With | 2 (4.76%) | 2 (4.65%) | 0.001 | 0.683 |
| Without | 40 (95.24%) | 41 (95.35%) | |||
| Liver abscess | With | 1 (2.38%) | 1 (2.33%) | 0.000 | 0.747 |
| Without | 41 (97.62%) | 42 (97.67%) | |||
| Inguinal hematoma | With | 2 (4.76%) | 3 (6.98%) | 0.188 | 0.511 |
| Without | 40 (95.24%) | 40 (93.02%) | |||
Abbreviation: TACE, transarterial chemoembolization.